All In Biotech

Drug Trial Radar · NCT06439082

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

A Phase III, Multicenter, Randomized, Placebo Controlled, Double-blind Study to Assess Efficacy and Safety of Crizanlizumab (5 mg/kg) Versus Placebo, With or Without Hydroxyurea/Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Frequent Vaso-Occlusive Crises

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 354 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

354

Planned (sponsor's estimate)

Start

Oct 24, 2024

Primary completion

Jul 2, 2029

Study completion Jul 29, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.

Conditions

  • Sickle Cell Disease

Interventions

  • CrizanlizumabBiological

    Crizanlizumab is supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for IV infusion.

  • PlaceboDrug

    Placebo is supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized rate of VOCs that are healthcare professional (HCP)-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) in each treatment armTime frame: 1 year

Locations

36 sites in 5 countries. Site status is shown where the registry gives one.

  • University Of Alabama

    Birmingham, Alabama · Recruiting

  • Ctr for Inherited Blood Disorders

    Orange, California · Recruiting

  • Childrens National Hospital

    Washington D.C., District of Columbia · Recruiting

  • University of Florida

    Jacksonville, Florida · Recruiting

  • Augusta University Georgia

    Augusta, Georgia · Recruiting

  • WCG Sonar Clinical Research

    Riverdale, Georgia · Recruiting

  • Uni of Illinois Hospital and HSC

    Chicago, Illinois · Recruiting

  • Norton Children s Hospital

    Louisville, Kentucky · Recruiting

  • The Johns Hopkins University School of Medicine

    Baltimore, Maryland · Recruiting

  • Southern Specialty Research

    Flowood, Mississippi · Recruiting

  • Childrens Hospital at Montefiore

    The Bronx, New York · Recruiting

  • East Carolina University

    Greenville, North Carolina · Recruiting

  • Wake Forest University Baptist Medical Center

    Winston-Salem, North Carolina · Recruiting

  • Spoknwrdclinicaltrials

    Easton, Pennsylvania · Withdrawn

  • Thomas Jefferson University Me

    Philadelphia, Pennsylvania · Recruiting

  • Texas Childrens Cancer and Hematology Center

    Houston, Texas · Recruiting

  • U of TX Health Science Ct

    Houston, Texas · Recruiting

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil · Recruiting

  • Novartis Investigative Site

    São Luís, Maranhão, Brazil · Recruiting

  • Novartis Investigative Site

    Campinas, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    Ribeirão Preto, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    Sao Jose Rio Preto, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Recruiting

  • Novartis Investigative Site

    Montería, Colombia · Recruiting

  • Novartis Investigative Site

    Medellín, Antioquia, Colombia · Recruiting

  • Novartis Investigative Site

    Cali, Valle del Cauca Department, Colombia · Recruiting

  • Novartis Investigative Site

    Cali, Valle del Cauca Department, Colombia · Recruiting

  • Novartis Investigative Site

    Eldoret, Kenya · Recruiting

  • Novartis Investigative Site

    Kisumu, Kenya · Recruiting

  • Novartis Investigative Site

    Kisumu, Kenya · Recruiting

  • Novartis Investigative Site

    Siaya, Kenya · Recruiting

  • Novartis Investigative Site

    Ahero, Kisumu County, Kenya · Recruiting

  • Novartis Investigative Site

    Kampala, Uganda · Recruiting

  • Novartis Investigative Site

    Masaka, Uganda · Recruiting

  • Novartis Investigative Site

    Tororo, Uganda · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.